AnaptysBio gives investors a rash as its big bet on eczema fails, sinking stock
When it comes to atopic dermatitis, Dupixent is king. AnaptysBio has now officially tried and failed to usurp the throne, conceding its lead drug failed a trial in patients with the chronic inflammatory skin condition.
Regeneron and Sanofi’s blockbuster Dupixent, known chemically as dupilumab, was the first biologic to win approval for moderate-to-severe AD, in patients who cannot tolerate or do not adequately benefit from topical prescription therapies. The market for AD, which is estimated to affect some 24 million Americans, is expected to hit $18.3 billion by 2027, according to GlobalData.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 65,000+ biopharma pros reading Endpoints daily — and it's free.